Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ARVN Stock Forecast 2025-2026
$12.79
Current Price
$978.66M
Market Cap
Buy 9
Hold 9
Sell 1
Wall St Analyst Ratings
Distance to ARVN Price Targets
+40.7%
To High Target of $18.00
+1.6%
To Median Target of $13.00
-53.1%
To Low Target of $6.00
ARVN Price Momentum
+8.3%
1 Week Change
+20.3%
1 Month Change
-50.7%
1 Year Change
-33.3%
Year-to-Date Change
-52.2%
From 52W High of $26.78
+116.8%
From 52W Low of $5.90
📊 TOP ANALYST CALLS
Did ARVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Arvinas is one of their latest high-conviction picks.
Latest ARVN Stock Price Targets & Analyst Predictions
Based on our analysis of 28 Wall Street analysts, ARVN has a neutral consensus with a median price target of $13.00 (ranging from $6.00 to $18.00). The overall analyst rating is Buy (7.5/10). Currently trading at $12.79, the median forecast implies a 1.6% upside. This outlook is supported by 9 Buy, 9 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Andrew S. Fein at HC Wainwright & Co., projecting a 40.7% upside. Conversely, the most conservative target is provided by Paul Choi at Goldman Sachs, suggesting a 53.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ARVN Analyst Ratings
9
Buy
9
Hold
1
Sell
ARVN Price Target Range
Low
$6.00
Average
$13.00
High
$18.00
Current: $12.79
Latest ARVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ARVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 10, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Maintains | $15.00 |
| Nov 6, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $15.00 |
| Nov 6, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $16.00 |
| Oct 30, 2025 | BTIG | Jeet Mukherjee | Buy | Maintains | $14.00 |
| Oct 15, 2025 | Goldman Sachs | Paul Choi | Sell | Downgrade | $6.00 |
| Sep 18, 2025 | BTIG | Jeet Mukherjee | Buy | Maintains | $10.00 |
| Sep 18, 2025 | Stephens & Co. | Sudan Loganathan | Overweight | Maintains | $14.00 |
| Sep 17, 2025 | Barclays | Etzer Darout | Overweight | Assumes | $16.00 |
| Aug 7, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $15.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Andrew S. Fein | Buy | Maintains | $18.00 |
| Aug 7, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $16.00 |
| Jun 2, 2025 | Leerink Partners | Andrew Berens | Market Perform | Downgrade | $9.00 |
| May 15, 2025 | UBS | Eliana Merle | Buy | Maintains | $21.00 |
| May 9, 2025 | Morgan Stanley | Terence Flynn | Equal-Weight | Maintains | $11.00 |
| May 5, 2025 | BMO Capital | Evan David Seigerman | Outperform | Maintains | $10.00 |
| May 5, 2025 | Citigroup | Yigal Nochomovitz | Neutral | Maintains | $9.50 |
| May 5, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Downgrade | $11.00 |
| May 2, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $24.00 |
| May 2, 2025 | Goldman Sachs | Paul Choi | Neutral | Maintains | $8.00 |
| May 2, 2025 | Jefferies | Akash Tewari | Hold | Downgrade | $10.00 |
Arvinas Inc. (ARVN) Competitors
The following stocks are similar to Arvinas based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Arvinas Inc. (ARVN) Financial Data
Arvinas Inc. has a market capitalization of $978.66M with a P/E ratio of -4.8x. The company generates $312.30M in trailing twelve-month revenue with a -18.7% profit margin.
Revenue growth is -59.1% quarter-over-quarter, while maintaining an operating margin of -105.0% and return on equity of -10.2%.
Valuation Metrics
Market Cap
$978.66M
Enterprise Value
$43.13M
P/E Ratio
-4.8x
PEG Ratio
0.2x
Price/Sales
3.0x
Growth & Margins
Revenue Growth (YoY)
-59.1%
Gross Margin
N/A
Operating Margin
-105.0%
Net Margin
-18.7%
EPS Growth
-59.1%
Financial Health
Cash/Price Ratio
+95.9%
Current Ratio
5.7x
Debt/Equity
1.6x
ROE
-10.2%
ROA
-6.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Arvinas Inc. (ARVN) Business Model
About Arvinas Inc.
What They Do
Develops innovative protein degradation therapies.
Business Model
The company utilizes a proprietary technology platform called PROTAC to create therapies that target and degrade disease-causing proteins. By focusing on previously undruggable targets, Arvinas aims to generate revenue through the development and commercialization of novel treatments for complex diseases such as cancer and neurodegenerative disorders, which are currently unmet medical needs.
Additional Information
Founded in 2013 and based in New Haven, Connecticut, Arvinas is actively engaged in clinical trials to test the safety and efficacy of its therapies. The company's innovative approach positions it at the forefront of the biotechnology sector, contributing to advancements in targeted therapy and drug development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
430
CEO
Dr. John G. Houston Ph.D.
Country
United States
IPO Year
2018
Website
www.arvinas.comArvinas Inc. (ARVN) Latest News & Analysis
Latest News
Quick Summary
Arvinas, Inc. (Nasdaq: ARVN) plans to initiate a Phase 1 trial for ARV-393 and glofitamab in diffuse large B-cell lymphoma in 2026, following positive preclinical data presented at ASH 2025.
Why It Matters
The initiation of a new clinical trial for ARV-393 combined with glofitamab could lead to significant advancements in DLBCL treatment, impacting Arvinas' market position and stock potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arvinas, Inc. (Nasdaq: ARVN) executives will discuss the company’s drug development at the Piper Sandler Healthcare Conference on December 4 at 11:00 a.m. ET in New York.
Why It Matters
The participation of Arvinas executives in a major healthcare conference can signal potential insights into drug development progress and financial strategy, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arvinas, Inc. (Nasdaq: ARVN) announced that abstracts on vepdegestrant (ARV-471) will be presented at the San Antonio Breast Cancer Symposium from December 9-12, 2025.
Why It Matters
The acceptance of multiple abstracts for vepdegestrant at a prominent symposium signals strong research interest, potentially boosting Arvinas' stock value and investor confidence in its drug pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arvinas, Inc. (ARVN) will hold its Q3 2025 earnings call on November 5, 2025, at 8:00 AM EST, featuring key executives and analysts from various financial institutions.
Why It Matters
The earnings call provides insights into Arvinas' financial performance and strategic direction, which can influence stock valuations and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
The company reported positive Phase 1 trial results for ARV-102 in Parkinson's patients, preclinical successes for ARV-806 and ARV-027, and a partnership with Pfizer for vepdegestrant's commercialization.
Why It Matters
Positive clinical trial results and strategic partnerships can enhance a company's growth prospects, attract investment, and potentially increase stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Arvinas, Inc. (ARVN) reported a quarterly loss of $0.48 per share, better than the expected loss of $0.75, compared to a loss of $0.68 per share in the same quarter last year.
Why It Matters
Arvinas, Inc.'s smaller-than-expected quarterly loss signals improving financial performance, potentially boosting investor confidence and driving stock price upward.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ARVN Stock
What is Arvinas Inc.'s (ARVN) stock forecast for 2026?
Based on our analysis of 28 Wall Street analysts, Arvinas Inc. (ARVN) has a median price target of $13.00. The highest price target is $18.00 and the lowest is $6.00.
Is ARVN stock a good investment in 2026?
According to current analyst ratings, ARVN has 9 Buy ratings, 9 Hold ratings, and 1 Sell ratings. The stock is currently trading at $12.79. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ARVN stock?
Wall Street analysts predict ARVN stock could reach $13.00 in the next 12 months. This represents a 1.6% increase from the current price of $12.79. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Arvinas Inc.'s business model?
The company utilizes a proprietary technology platform called PROTAC to create therapies that target and degrade disease-causing proteins. By focusing on previously undruggable targets, Arvinas aims to generate revenue through the development and commercialization of novel treatments for complex diseases such as cancer and neurodegenerative disorders, which are currently unmet medical needs.
What is the highest forecasted price for ARVN Arvinas Inc.?
The highest price target for ARVN is $18.00 from Andrew S. Fein at HC Wainwright & Co., which represents a 40.7% increase from the current price of $12.79.
What is the lowest forecasted price for ARVN Arvinas Inc.?
The lowest price target for ARVN is $6.00 from Paul Choi at Goldman Sachs, which represents a -53.1% decrease from the current price of $12.79.
What is the overall ARVN consensus from analysts for Arvinas Inc.?
The overall analyst consensus for ARVN is neutral. Out of 28 Wall Street analysts, 9 rate it as Buy, 9 as Hold, and 1 as Sell, with a median price target of $13.00.
How accurate are ARVN stock price projections?
Stock price projections, including those for Arvinas Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 8, 2025 9:55 PM UTC